Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
stocks
Our view of ANZ’s strategic plan
Trying to please customers and shareholders with a simpler and leaner bank.
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,275.00 | 2.10 | -0.02% |
| CAC 40 | 7,919.62 | 14.64 | -0.18% |
| DAX 40 | 24,236.94 | 150.99 | -0.62% |
| Dow JONES (US) | 46,270.46 | 202.88 | 0.44% |
| FTSE 100 | 9,452.77 | 9.90 | 0.10% |
| HKSE | 25,846.88 | 405.53 | 1.59% |
| NASDAQ | 22,521.70 | 172.91 | -0.76% |
| Nikkei 225 | 47,389.82 | 542.50 | 1.16% |
| NZX 50 Index | 13,297.38 | 20.39 | 0.15% |
| S&P 500 | 6,644.31 | 10.41 | -0.16% |
| S&P/ASX 200 | 8,968.40 | 0.30 | -0.00% |
| SSE Composite Index | 3,885.96 | 20.73 | 0.54% |